TWO · 4116.TWO
BenQ Medical Technology Corporation
NT$44.20+NT$1.35 (+3.15%)
BenQ Medical Technology Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.42% below the high.
Loading market information…
TWO · 6730.TWO · TWD
Stock price, dividends
Quote as of Oct 30, 2026, 04:15 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Lagis Enterprise Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Lagis Enterprise Co., Ltd.’s forward annual dividend is NT$1.50 per share, paid annual. The forward yield is 4.67% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
Lagis Enterprise Co., Ltd. is a medical technology company focused on the development and global distribution of specialized devices for laparoscopic and endoscopic surgical procedures. Their comprehensive product portfolio includes trocars, single-port surgery systems, and wound protectors. They also offer a range of endo devices, such as precision hand instruments and advanced bipolar tools, alongside specimen retrieval products, suction-irrigation systems and pumps, surgical training solutions, and various related accessories. Founded in 1993, the company maintains its headquarters in Taichung, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:49 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$44.20+NT$1.35 (+3.15%)
BenQ Medical Technology Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.42% below the high.
NT$72.10-NT$0.40 (-0.55%)
Crystalvue Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 13.45% below the high.
NT$28.50-NT$0.15 (-0.52%)
Chi Sheng Pharma & Biotech Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 7.92% below the high.
NT$18.70-NT$0.15 (-0.8%)
NaviFUS Corp.’s quoted price sits in the lower half of its reported 52-week range, 30.87% below the high.
NT$17.60-NT$0.10 (-0.56%)
Arich Enterprise Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.67% below the high.
NT$21.20+NT$0.20 (+0.95%)
Bioptik Technology Incorporation’s quoted price sits in the lower half of its reported 52-week range, 24.29% below the high.
NT$17.20+NT$0.05 (+0.29%)
Perfect Medical Industry Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.2% below the high.
NT$14.90-NT$0.40 (-2.61%)
Enimmune corporation’s quoted price sits in the lower half of its reported 52-week range, 33.92% below the high.
